We extended our previous GWAS for psoriasis with a a multistage replication study including 8,312 cases and 12,919 controls from China as well as 3,293 cases, 4,188 controls from Germany and the USA, and 254 nuclear families from the USA. We identified 6 new susceptibility loci associated to psoriasis in Chinese, containing candidate genes ERAP1, PTTG1, CSMD1, GJB2, SERPINB8, ZNF816A (PCombined<5×10−8) and replicated one locus 5q33.1 (TNIP1/ANXA6) previously reported (PCombined=3.8×10−21) in European studies. Two of these loci showed evidence for association evidence in the German study, at ZNF816A and GJB2 with P=3.6×10−3 and P=7.9×10−3, respectively. ERAP1 and ZNF816A were preferentially associated with Type I (early onset) psoriasis in Chinese Han population (test for heterogeneity P=6.5×10−3 and P=1.5×10−3, respectively). Comparisons with previous GWAS of psoriasis highlight the heterogeneity of disease susceptibility between Chinese and European populations. Our study identifies new genetic susceptibility factors and suggests new biological pathways in psoriasis.

Mots clés: enseignement sur le diabète pied diabétique soins de pieds prévention a b s t r a c t Objective: The aim of this study is to design and implement a foot care program for minority patients with type 2 diabetes mellitus of Zhuang tribe in Guangxi, China, which will achieve the following: 1) improve patients' foot care behaviour, 2) improve their glycated hemoglobin (A1C) and 3) decrease the incidence of foot ulcers and amputation. Background: In Guangxi, China, foot care resources are limited, and diabetes self-management and foot care is poor for patients with diabetes. Thus developing a program with the limited resources for diabetes foot care is very important. Methods: A multidisciplinary team led by a diabetes nurse was established. A foot care kit and set of teaching materials focusing on foot care and diabetes self-management was developed. Sixty-two inpatients with type 2 diabetes mellitus, under the same attending physician's service, were screened to be at high risk for foot ulcers and randomized into 2 groups. The subjects in the study group received didactic diabetes education, tailored foot care and focused teaching for 2 hours. Every patient was given a foot care kit during hospitalization and then followed up in the clinic monthly with a systematic foot exam. Subsequently, diabetes education classes were given every 3 to 6 months. The subjects in the control group were just given usual care according to 2007 Americans with Disabilities Act standards. Results: For patients in the study group, the average score of knowledge and self foot care behaviours were higher than those of the patients in the control group both after 1 year (88.31 AE 8.15, 86.35 AE 5.17 vs. 70.27 AE 7.92, 75.86 AE 6.19) and 2 years (87.24 AE 6.20, 89.56 AE 7.00 vs. 71.43 AE 5.17, 67.87 AE 5.26). The mean A1C (6.5% AE 2.3% vs. 7.9% AE 4.2%), the incidence of foot ulcer (0% vs. 24.14%), and amputation (0% vs. 6.90%) were much lower than that of the patients in the control group after 2 years. Conclusion: The foot care program delivered by a multidisciplinary team can markedly improve foot care behaviours and reduce complications of the minority diabetes patients who are at risk of developing foot ulcer, thereby reducing the incidence of foot ulcer and amputation. In areas where resources are limited, the foot care program will be a cost-effective approach to reduce the incidence of diabetes foot ulcer.Ó 2012 Canadian Diabetes Association r é s u m é Objectifs : Le but de cette étude est de concevoir et de mettre en oeuvre un programme de soins de pieds pour les patients minoritaires de la tribu Zhuang, en Chine, ayant un diabète sucré de type 2 (DST2), qui permettra d'atteindre les objectifs suivants: 1) améliorer les habitudes des patients en ce qui a trait aux soins des pieds; 2) améliorer leur HbA1c; 3) diminuer l'incidence des ulcères du pied et de l'amputation. Introduction : Dans la région du Guangxi, en Chine, les ressources en soins de pieds sont limitées, et la prise en charge autonome du diabète et les soins de...

Background:Conflicting results have been reported on the association of poststroke depression with recurrent stroke events. This meta-analysis of prospective studies aims to evaluate whether poststroke depression is an independent predictor of stroke recurrence among stroke patients.Methods:A systematic search of articles in PubMed and Embase databases from their inception to October 2018 was conducted. Prospective studies reporting risk estimates of stroke recurrence by depression status in stroke patients were included and pooled risk ratio (RR) with 95% confidence intervals (CIs) of stroke recurrence was calculated for patients with or without poststroke depression.Results:Six studies with 4648 stroke patients were finally included, and the prevalence of poststroke depression was found to from 15.9% to 40.5%. The pooled adjusted RR for stroke recurrence in patients suffering from poststroke depression was 1.48 (1.22–1.79) in a fixed-effect model. Subgroup analyses indicated that poststroke depression significantly increased stroke recurrence (RR 1.64; 95% CI, 1.28–2.10) among ischemic stroke patients but not in total stroke patients (RR 1.28; 95% CI, 0.96–1.73).Conclusions:This meta-analysis suggests that poststroke depression may be an independent predictor of stroke recurrence among ischemic stroke patients. Further studies are required to investigate whether treatment of poststroke depression can reduce the risk of stroke recurrence.

The aim of this study was to compare the efficacy and safety of S-1-based therapy versus non-S-1-based therapy in advanced gastric cancer (AGC) patients.Eligible studies stratifying objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) in AGC patients were identified from Embase, Pubmed, Cochrane Library, and China National Knowledge Infrastructure databases. The STATA package (version 11.0) was used to pool the data from the eligible studies.Fifteen studies with 2973 AGC cases, of which 1497 (50.4%) received S-1-based therapy and 1476 (49.6%) received non-S-1-based therapy, were identified in the meta-analysis. AGC patients who had received S-1-based therapy had a higher median OS, median PFS, and ORR than those who had received 5-fluorouracil (FU)-based therapy (OS: hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.80–0.98, P = 0.015; PFS: HR 0.88, 95% CI 0.80–0.98, P = 0.016; ORR: OR 1.25, 95% CI 1.08–1.45, P = 0.003, respectively). S-1-based therapy had similar efficacy to capecitabine-based therapy in terms of median OS (HR 1.14, 95% CI 0.91–1.41, P = 0.253), median PFS (HR 1.01, 95% CI 0.82–1.25, P = 0.927), and ORR (OR 0.84, 95% CI 0.63–1.12, P = 0.226). Subgroup analysis for grade 3 to 4 toxicity showed higher incidence of neutropenia (relative risk [RR] = 0.827, P = 0.006), nausea (RR = 0.808, P = 0.040), and lower diarrhea (RR = 1.716, P = 0.012) in 5-FU-based arm, and higher diarrhea (RR = 0.386, P = 0.007) in capecitabine-based arm.S-1-based chemotherapy is favorable to AGC patients with better clinical benefit than 5-FU-based chemotherapy and with equivalent antitumor compare with capecitabine-based therapy.